Shots:

• The P-IIb study involves assessing SAR442168 vs PBO in patients with recurring MS. The one group of patients received 4 doses of SAR442168 @12wks.- then crossed over to PBO @4wks. while the other group of patients received PBO @4wks. before crossing over to SAR442168
• The P-IIb study resulted in meeting its 1EPs i.e. reduction in disease activity associated with MS as measured by MRI- demonstrated reduction of gadolinium (Gd)-enhancing T1-hyperintense brain lesions @12wks. and is well tolerated with no new safety signals
• SAR442168 (PO) is an investigational- brain penetrant BTK inhibitor with its anticipated initiation of P-III studies in mid-2020. Additionally- Sanofi got global rights to develop and commercialize SAR442168 under a license agreement with Principia Biopharma signed in Nov’2017

Click here ­to­ read full press release/ article | Ref: Sanofi  | Image: Youtube